Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi ... in the class to be approved after Bristol-Myers Squibb's well-established Yervoy ...

Bristol-Myers Squibb has won FDA approval for the first ... ballpark as the Opdivo/Yervoy combination for melanoma. BMS sues AZ, claiming Imfinzi infringes Opdivo patents BMS, meanwhile, has ...

Curatis Holding (SIX:CURN) announces today the formation of an Advisory Board comprised of four internationally recognized experts across multiple medical and scientific disciplines. The board brings ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

The stock's fall snapped a four-day winning streak.

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s ...

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend stocks. Dividend stocks have taken a backseat in the market as ...